Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies
- PMID: 33995113
- PMCID: PMC8115909
- DOI: 10.3389/fphar.2021.685604
Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies
Keywords: European commission; added value; drug development—clinical trials; health policies; incentives; pharmaceutical medicine; pharmaceutical policies.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- Boulet P., Garrison C., Ellen’t Hoen E. (2019). European Union Review of Pharmaceutical Incentives: Suggestions for Change. Available at: https://medicineslawandpolicy.org/wp-content/uploads/2019/06/MLP-Europea... (Accessed March 18, 2021)
-
- Ellen’t Hoen E. (2020). Some Surprises in the European Commission’s New Intellectual Property Strategy. Available at: https://medicineslawandpolicy.org/2020/12/some-surprises-in-the-european... (Accessed March 18, 2021)
-
- European Commission (2020a). Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. A Pharmaceutical Strategy for Europe. Available at: https://ec.europa.eu/health/human-use/strategy_en (Accessed March 18, 2021)
-
- European Commission (2020b). Evaluation of the Orphan and Paediatric Regulation. Available at: https://ec.europa.eu/health/sites/health/files/files/committee/ev_202003... (Accessed March 18, 2021)
-
- European Commission (2020c). Commission Adopts Action Plan on Intellectual Property to Strengthen EU's Economic Resilience and Recovery. Available at: https://ec.europa.eu/commission/presscorner/detail/en/IP_20_2187 (Accessed March 18, 2021)
LinkOut - more resources
Full Text Sources
Other Literature Sources
